Significant Options Activity on Monday: MO, IMNM, RSI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy IMNM?
Source: NASDAQ.COM
Immunome Inc Options Activity: Immunome Inc (IMNM) experienced significant options trading with 6,200 contracts, equating to about 620,000 underlying shares, notably for the $25 strike call option expiring December 19, 2025.
Rush Street Interactive Inc Options Activity: Rush Street Interactive Inc (RSI) also saw high options trading volume of 5,715 contracts, representing approximately 571,500 underlying shares, particularly for the $20 strike call option expiring December 19, 2025.
Trading Volume Comparison: The options trading volumes for both IMNM and RSI represent over 50% of their respective average daily trading volumes over the past month.
Further Information: For additional details on available options expirations for IMNM, RSI, or other stocks, StockOptionsChannel.com can be visited.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNM
Wall Street analysts forecast IMNM stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.440
Low
21.00
Averages
33.20
High
40.00
Current: 22.440
Low
21.00
Averages
33.20
High
40.00
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Impact: While specific stocks are not detailed, such rating changes typically influence investor decisions, thereby directly impacting the stock prices of the companies involved.
- Source of Updates: A complete view of all analyst rating changes can be found on our analyst ratings page, offering a comprehensive understanding of market dynamics.
- Lack of Investment Advice: Although the report provides information on rating changes, it does not offer specific investment advice, leaving investors to make their own judgments.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
Market Overview: Energy Stocks Show Strength
- Market Performance Overview: Last week, the S&P 500 gained 0.34%, while the Nasdaq and Dow Jones fell by 0.17% and 0.42%, respectively, indicating market divergence and suggesting that investors should remain cautious as February approaches, a historically weaker month.
- Energy Stock Potential: Energy Fuels Inc. (UUUU), focused on uranium mining, reported $24.9 million in revenue last quarter with no earnings, yet its astronomical Price-to-Sales ratio of 63.50 reflects strong market expectations for future growth, with an anticipated 81% upside potential.
- Technical Indicator Analysis: UUUU is forming a saucer pattern, and if it breaks above the resistance zone, it could trigger a new upward phase, making the $18.50 to $19.00 support level critical for investors to monitor.
- Market Volatility Warning: Despite the S&P 500 hitting an all-time high last week, the Nasdaq failed to break out, suggesting potential volatility ahead; investors should seize buying opportunities, particularly before the upcoming Federal Reserve meeting.
See More
IMNM Options Analysis: Put Contract Offers 27.5% YieldBoost
- Put Contract Yield: The $20.00 put contract for IMNM has a current bid of $5.50, and if an investor sells it, they commit to buying shares at $20.00, resulting in a cost basis of $14.50, making it an attractive alternative to the current price of $20.16.
- Expiration Worthless Probability: The odds of the put contract expiring worthless are 75%, and if it does, the premium would yield a 27.5% return on cash commitment, or 13.6% annualized, highlighting the strategy's potential appeal.
- Call Contract Returns: The $22.00 call contract has a current bid of $6.50, and if an investor buys IMNM shares at $20.16 and sells this call, they could achieve a total return of 41.37% if the stock is called away at January 2028 expiration, indicating strong profit potential.
- Call Contract Expiration Worthless Probability: The call contract has a 28% chance of expiring worthless, allowing investors to keep both their shares and the premium collected, with an additional return of 32.24%, or 15.95% annualized, further enhancing the investment's attractiveness.
See More
Insider Buying Update for Friday, December 19: IMNM and S
Immunome Insider Purchase: Immunome's CEO, Clay B. Siegall, bought 46,511 shares of IMNM for $999,986 at $21.50 each, following previous investments totaling $2.16M at an average of $7.53 per share.
SentinelOne Insider Purchase: Director Mark S. Peek of SentinelOne purchased 40,000 shares at $14.89 each for a total of $595,600, while the stock is currently trading lower at $14.61.
Market Performance: Immunome's stock rose approximately 7.9% on Friday, while SentinelOne's stock saw a slight increase of 0.3%.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Impact: While specific stocks are not detailed, such rating changes typically influence investor decisions, thereby directly impacting the stock prices of the companies involved.
- Source of Updates: A complete view of all analyst rating changes can be found on our analyst ratings page, offering a comprehensive understanding of market dynamics.
- Lack of Investment Advice: Although the report provides information on rating changes, it does not offer specific investment advice, leaving investors to make their own judgments.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
Market Overview: Energy Stocks Show Strength
- Market Performance Overview: Last week, the S&P 500 gained 0.34%, while the Nasdaq and Dow Jones fell by 0.17% and 0.42%, respectively, indicating market divergence and suggesting that investors should remain cautious as February approaches, a historically weaker month.
- Energy Stock Potential: Energy Fuels Inc. (UUUU), focused on uranium mining, reported $24.9 million in revenue last quarter with no earnings, yet its astronomical Price-to-Sales ratio of 63.50 reflects strong market expectations for future growth, with an anticipated 81% upside potential.
- Technical Indicator Analysis: UUUU is forming a saucer pattern, and if it breaks above the resistance zone, it could trigger a new upward phase, making the $18.50 to $19.00 support level critical for investors to monitor.
- Market Volatility Warning: Despite the S&P 500 hitting an all-time high last week, the Nasdaq failed to break out, suggesting potential volatility ahead; investors should seize buying opportunities, particularly before the upcoming Federal Reserve meeting.
See More
IMNM Options Analysis: Put Contract Offers 27.5% YieldBoost
- Put Contract Yield: The $20.00 put contract for IMNM has a current bid of $5.50, and if an investor sells it, they commit to buying shares at $20.00, resulting in a cost basis of $14.50, making it an attractive alternative to the current price of $20.16.
- Expiration Worthless Probability: The odds of the put contract expiring worthless are 75%, and if it does, the premium would yield a 27.5% return on cash commitment, or 13.6% annualized, highlighting the strategy's potential appeal.
- Call Contract Returns: The $22.00 call contract has a current bid of $6.50, and if an investor buys IMNM shares at $20.16 and sells this call, they could achieve a total return of 41.37% if the stock is called away at January 2028 expiration, indicating strong profit potential.
- Call Contract Expiration Worthless Probability: The call contract has a 28% chance of expiring worthless, allowing investors to keep both their shares and the premium collected, with an additional return of 32.24%, or 15.95% annualized, further enhancing the investment's attractiveness.
See More
Insider Buying Update for Friday, December 19: IMNM and S
Immunome Insider Purchase: Immunome's CEO, Clay B. Siegall, bought 46,511 shares of IMNM for $999,986 at $21.50 each, following previous investments totaling $2.16M at an average of $7.53 per share.
SentinelOne Insider Purchase: Director Mark S. Peek of SentinelOne purchased 40,000 shares at $14.89 each for a total of $595,600, while the stock is currently trading lower at $14.61.
Market Performance: Immunome's stock rose approximately 7.9% on Friday, while SentinelOne's stock saw a slight increase of 0.3%.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
